- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05526391
En undersøgelse af TAK-341 i behandling af multipel systematrofi
Et randomiseret, dobbeltblindt, placebokontrolleret, fase 2-studie til evaluering af effektivitet, sikkerhed, tolerabilitet, farmakokinetik og farmakodynamik af intravenøs TAK-341 hos forsøgspersoner med multipel systematrofi
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS).
The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed.
This trial will be conducted in North America, Europe and Asia.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The drug being tested in this study is called TAK-341. The study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of intravenous (IV) TAK-341 in participants with multiple system atrophy (MSA).
The study will enroll approximately 158 participants. The study comprises a screening period of up to 42 days (6 weeks), a 52-week double-blind treatment period, and a follow-up safety visit. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant, care provider and investigator during the study:
- TAK-341
- Placebo
The change from baseline in UMSARS will be measured at Week 52 post-dose.
This multi-center trial will be conducted worldwide. The duration of treatment in this study will be 52 weeks. Participants will make a follow-up visit to the site after approximately 90 days after the last dose of study treatment.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Aarhus N, Danmark, 8200
- Aarhus Universitetshospital
-
-
Capital
-
København NV, Capital, Danmark, 2400
- Bispebjerg Hospital
-
-
-
-
Hampshire
-
Southampton, Hampshire, Det Forenede Kongerige, SO16 6YD
- Southampton General Hospital
-
-
-
-
Michigan
-
Farmington Hills, Michigan, Forenede Stater, 48025
- Quest Research Institute - Alcanza - HyperCore
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905-0001
- Mayo Clinic
-
-
New York
-
New York, New York, Forenede Stater, 10016-6402
- NYU Langone Health
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705-4410
- Duke University School of Medicine
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- The Cleveland Clinic Foundation
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390-7208
- University of Texas Southwestern Medical Center
-
-
Washington
-
Spokane, Washington, Forenede Stater, 99202-1342
- Inland Northwest Research
-
-
-
-
Bouches-du-Rhone
-
Marseille, Bouches-du-Rhone, Frankrig, 13385
- Hopitaux de La Timone
-
-
-
-
-
Salerno, Italien, 84131
- Azienda Ospedaliera Universitaria OO.RR. San Giovanni di Dio Ruggi dAragona
-
-
Lazio
-
Rome, Lazio, Italien, 00163
- IRCCS San Raffaele Roma
-
-
Lombardy
-
Milan, Lombardy, Italien, 20133
- Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta
-
Milan, Lombardy, Italien, 20122
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
-
Rozzano, Lombardy, Italien, 20089
- Istituto Clinico Humanitas
-
-
Veneto
-
Padova, Veneto, Italien, 35126
- Azienda Ospedale Universita Padova
-
-
-
-
Chiba
-
Chuo-ku, Chiba, Japan, 260-8677
- Chiba University Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8638
- Hokkaido University Hospital
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 606-8507
- Kyoto University Hospital
-
-
Tokyo
-
Bunkyo-Ku, Tokyo, Japan, 113-0033
- The University of Tokyo Hospital
-
Bunkyo-Ku, Tokyo, Japan, 113-8519
- Medical Hospital of Tokyo Medical and Dental University
-
Kodaira-Shi, Tokyo, Japan, 187-8551
- National Center of Neurology and Psychiatry
-
-
-
-
Lisbon District
-
Loures, Lisbon District, Portugal, 2674-514
- Campus Neurologico Senior
-
-
Porto District
-
Senhora da Hora, Porto District, Portugal, 4464-513
- Hospital Pedro Hispano
-
-
-
-
-
Barcelona, Spanien, 08035
- Hospital Universitario Vall d'Hebron
-
Barcelona, Spanien, 08041
- Hospital de La Santa Creu i Sant Pau
-
Madrid, Spanien, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Spanien, 28006
- Hospital Universitario de La Princesa
-
Valencia, Spanien, 46026
- Hospital Universitari i Politecnic La Fe de Valencia
-
-
Vizcaya
-
Barakaldo, Vizcaya, Spanien, 48903
- Hospital Universitario Cruces
-
-
-
-
-
Berlin, Tyskland, 10117
- Charite - Universitatsmedizin Berlin
-
-
Bavaria
-
München, Bavaria, Tyskland, 81377
- Klinikum Groshadern, LMU
-
-
Hesse
-
Kassel, Hesse, Tyskland, 34128
- Paracelsus-Elena-Klinik Kassel
-
-
Lower Saxony
-
Hanover, Lower Saxony, Tyskland, 30625
- Medizinische Hochschule Hannover
-
-
North Rhine-Westphalia
-
Bochum, North Rhine-Westphalia, Tyskland, 44791
- Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB) - St. Josef-Hospital
-
Bonn, North Rhine-Westphalia, Tyskland, 53127
- Deutsches Zentrum fur Neurodegenerative Erkrankung
-
Münster, North Rhine-Westphalia, Tyskland, 48149
- Universitatsklinikum Munster
-
-
Saxony
-
Dresden, Saxony, Tyskland, 01307
- Universitatsklinikum Carl Gustav Carus an der TU Dresden
-
Leipzig, Saxony, Tyskland, 04103
- Universitatsklinikum Leipzig
-
-
-
-
Styria
-
Graz, Styria, Østrig, 8036
- Medizinische Universitat Graz
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
Diagnostic:
- The participant has a diagnosis of possible or probable MSA using the modified Gilman et al, 2008 diagnostic criteria.
- The participant's onset of first MSA symptoms occurred ≤4 years before screening, as assessed by the investigator.
- Evidence of MSA specific symptoms and deficits as measured by the UMSARS scale.
Exclusion criteria:
Medical History:
1. The participant has any contraindication to study procedures.
Diagnostic Assessments:
- Presence of confounding diagnosis and/or conditions that could affect participant's safety during the study per investigator judgement.
- The participant's participation in a previous study of a disease-modifying therapy (with proven receipt of active treatment) will compromise the interpretability of the data from the present study, per consultation with medical monitor or designee.
Other:
1. The participant has participated in another study investigating active or passive immunization against α-synuclein (αSYN) for progressive disease (PD) or MSA, or has had immunoglobulin G therapy, within 6 months before screening.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
Participants received TAK-341 matching placebo intravenous (IV) infusions, once every 4 weeks (Q4W) for 52 weeks. |
TAK-341-matching placebo IV infusion |
|
Eksperimentel: TAK-341
Participants received TAK-341, IV Q4W for 52 weeks. An early set of participants initially received 2400 milligrams (mg) to determine pharmacokinetic (PK) parameters. Following the early participants, a dose of 2000 mg was given until the data from the PK participants became available. All participants then received 2400 mg until the end of treatment at 52 weeks. |
TAK-341 IV infusion
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52
Tidsramme: Baseline, Week 52
|
UMSARS Part I (historical review) is a 12-item scale that was adapted from the Unified Parkinson's Disease Rating Scale (UPDRS) and is used to assess activities related to motor disability and autonomic dysfunction. In this study, the UMSARS was modified to exclude the sexual function item. Thus, total 11 items were assessed. Each item was initially scored on a scale from 0 (normal) to 4 (severe); ratings of normal (0) and mild (1) were then combined and recorded as 0, making minimum score 0 and maximum score 3. The investigator rated the average functional situation for the past 2 weeks according to findings from the participant and caregiver interview and indicated the score that best fit with the participant's status. The total score is a sum of scores from all domains and range from 0 to 33. Higher scores indicate worse impairment. |
Baseline, Week 52
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Anti-Drug Antibodies
Tidsramme: Up to Week 61
|
Up to Week 61
|
|
|
Change From Baseline in 11-item UMSARS at Week 52
Tidsramme: Baseline, Week 52
|
The 11- item UMSARS includes 11 items from Part I and II to assess both motor and autonomic disability. UMSARS Part I (historical review) is used to assess activities related to motor disability and autonomic dysfunction. UMSARS Part II (motor examination) is used to measure the functional impairment and specific parkinsonian or cerebellar features. Each item was scored on a scale from 0 (normal) to 4 (severe); total score ranges from 0 to 44, higher scores indicated worse impairment. |
Baseline, Week 52
|
|
Change From Baseline in the UMSARS Total Score (UMSARS Part I + Part II) at Week 52
Tidsramme: Baseline, Week 52
|
UMSARS total scale consists of all items from UMSARS Parts I and II. UMSARS Part I (historical review): 12-item scale used to assess activities related to motor disability and autonomic dysfunction. Each item is scored from 0 (normal) to 4 (severe). UMSARS Part II (motor examination): 14-item scale used to measure the functional impairment (for example speech, rapid alternating movements of the hands, finger taps, leg agility) of selected complex movements, and specific parkinsonian (tremor at rest) or cerebellar (ocular motor dysfunction, heel-shin test) features. The worst affected limb was assessed, and each item was scored from 0 (normal) to 4 (severe). UMSARS Part I and Part II total score is the sum of UMSARS Part I and Part II and ranges from 0 to 104. A higher score indicates worse impairment. |
Baseline, Week 52
|
|
Change From Baseline in UMSARS Part I 11-Item Score at Week 52
Tidsramme: Baseline, Week 52
|
UMSARS Part I (historical review) is a 12-item scale that was adapted from the UPDRS. In this study, the UMSARS was modified to exclude the sexual function item. The UMSARS is used to assess activities related to motor disability and autonomic dysfunction. Each item was scored on a scale from 0 (normal) to 4 (severe). UMSARS Part I 11-item total score is the total score of UMSARS Part I, excluding the sexual function item, and without collapse of ratings of scale items. The UMSARS Part I 11-item total score ranges from 0 to 44, and higher scores indicate worse impairment. |
Baseline, Week 52
|
|
Change From Baseline in UMSARS Part II at Week 52
Tidsramme: Baseline, Week 52
|
UMSARS Part II (motor examination): 14-item scale used to measure the functional impairment (e.g., speech, rapid alternating movements of the hands, finger taps, leg agility) of selected complex movements, and specific parkinsonian (tremor at rest) or cerebellar (ocular motor dysfunction, heel-shin test) features. the worst affected limb was assessed, and each item was scored from 0 (normal) to 4 (severe). The UMSARS Part II total score ranges from 0 to 56, and higher scores indicate worse impairment. |
Baseline, Week 52
|
|
Change From Baseline on Clinical Global Impression-Severity (CGI-S) Score
Tidsramme: Baseline, Week 24 and Week 52
|
The CGI-S is used to assess the clinician's impression of the participant's clinical condition. The clinician rates the current severity of the participant's illness on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (most extremely ill). The rating was based on observed and reported symptoms, behaviour, and function and reflected the severity level at the time of the assessment. A higher score indicates worse impairment. |
Baseline, Week 24 and Week 52
|
|
Change From Baseline in Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA-AUT) Total Score
Tidsramme: Baseline, Week 24 and Week 52
|
The SCOPA-AUT is a participant-reported outcome that assesses autonomic function. Autonomic function is a critical symptom domain for MSA. The scale was completed by participants and consisted of 25 items assessing the following domains: gastrointestinal (7 items), urinary (6 items), cardiovascular (3 items), thermoregulatory (4 items), pupillomotor (1 item), and sexual (2 items for men and 2 items for women). The score for each item ranged from 0 (never experiencing the symptom) to 3 (often experiencing the symptom). The total composite score including all domains was reported. The score range was 0 (no symptoms) to 69 (highest burden of symptoms). A higher score indicates worse impairment. |
Baseline, Week 24 and Week 52
|
|
Overall Survival (OS) at Week 52
Tidsramme: At Week 52
|
OS was estimated with Kaplan-Meier survival estimates, along with 95% confidence interval. A cox proportional hazards model was fitted to model the survival probability with treatment as the predictor. The participants with missing value were censored. The probabilities of survival at Week 52 for participants were estimated and reported. |
At Week 52
|
|
Change From Baseline in Cerebrospinal Fluid (CSF) Free Alpha-Synuclein (αSYN)
Tidsramme: Baseline, Week 52
|
α-Synucleinopathies are diseases characterized by abnormal accumulation of aggregated αSYN. In participants with MSA, αSYN is seen to accumulate primarily in oligodendrocytes, forming glial cytoplasmic inclusions. A negative change from Baseline indicates an improvement. |
Baseline, Week 52
|
|
Maximum Observed Steady State Serum Concentration (Cmax) for TAK-341
Tidsramme: On Day 57- immediately before end of infusion (EOI) (60 minutes), 6 hours and 24 hours.
|
Cmax is the maximum observed serum concentration for TAK-341. |
On Day 57- immediately before end of infusion (EOI) (60 minutes), 6 hours and 24 hours.
|
|
Time to Maximum Steady State Concentration (Tmax) for TAK-341
Tidsramme: On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.
|
Tmax is the time of first occurrence of maximum observed concentration for TAK-341. |
On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.
|
|
Area Under the Serum Concentration Time Curve (AUCτ) at Steady State for TAK-341
Tidsramme: On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.
|
AUCτ is the area under the serum concentration-time curve during a dosing interval. |
On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.
|
|
CSF Concentration of TAK-341
Tidsramme: On Day 1, Day 85 and Day 365
|
Lumbar puncture was performed for CSF on Day 1, Day 85 and Day 365, predose. |
On Day 1, Day 85 and Day 365
|
|
Number of Participants With at Least One Adverse Event (AE)
Tidsramme: Up to Week 61
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event that occurs after administration of the first dose of study treatment and up through 90 days after the last dose of study treatment. |
Up to Week 61
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Medical Director, Takeda (Note: This product was divested to Alexion/AstraZeneca in 2026)
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- TAK-341-2001
- 2022-000336-28 (EudraCT nummer)
- jRCT2011220029 (Registry Identifier: jRCT)
- 2023-509876-40-00 (Ctis)
- 2023 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .